Take a look around the Penlon global headquarters located in the United Kingdom. Penlon is a world-class British medical device company, established in Oxford in 1943. Penlon develops, manufactures and exports anaesthesia and other medical products to over ninety countries worldwide, including China, Japan and the USA.
Take a look around the Penlon global headquarters located in the United Kingdom.
Penlon Global Headquarters Factory Tour
Penlon’s CEO talks about the ESO 2 ventilator and the VCUK consortium
Meet the CEO
Guru Krishnamoorthy, CEO of Penlon, talks about the ESO 2 Emergency Ventilator, the VentilatorChallengeUK (VCUK) consortium and working with consortium members such as Ford, Siemens Healthineers, Airbus and McLaren during the coronavirus pandemic.
The story of Penlon, VentilatorChallengeUK and the ESO 2 Emergency Ventilator
Penlon, VCUK and the ESO 2 Emergency Ventilator
On January 29th 2020 two Chinese nationals staying at a hotel in York, UK, fell ill. They would become the first recorded UK cases of the COVID-19 pandemic, an aggressive strain of the coronavirus that had not been previously identified in humans. As the virus took hold, so too did the demand for equipment to treat the sick. By mid-March, the Government had established that up to 30,000 ventilators may be required for the UK’s COVID-19 patients. It would soon become apparent that this was a serious issue because the UK does not make a suitable critical care ventilator, while established international providers were struggling to cope with their own domestic and international demand.
On March 17th the UK Government issued a ‘call to arms.’ An appropriate technology specification was drafted and the Rapid Manufacture Ventilator System ‘RMVS’ was conceived. Using its ventilation expertise, Penlon quickly responded by proposing the ESO 2 Emergency Ventilator, based on the existing AV-S anaesthesia ventilator platform.
The purpose of the ESO 2 is to save lives by ventilating the sickest patients until they are strong enough to be transferred to one of the limited number of ICU ventilators available for recovery. The first ESO 2 prototype was demonstrated less than a week later and the ‘Ventilator Challenge UK’ consortium was formed to manufacture the ESO 2 in large numbers.
In a matter of days, Penlon successfully transformed the company from a daytime batch production business to a 24/7 operation providing technical back-up to the consortium manufacturing sites and final testing and despatch of the ESO 2 to the NHS.
By April 13th, after receiving MHRA approval, the first ESO 2 production units were despatched and just a few days later, installed at the newly established 4000 bed NHS Nightingale Hospital in London.
Today the company’s UK factory in Oxfordshire is dedicated completely to the ESO 2 project. Penlon’s regular business of Anaesthesia Systems, Patient Monitoring, Laryngoscopes and Suction and Oxygen Therapy will only recommence when the ESO 2 delivery objectives have been met. Thereafter, Penlon plans to offer the ESO 2 overseas, wherever the need for COVID-19 treatment exists.
Penlon’s Craig Thompson, said,
"We are delighted to have been given the opportunity to dedicate our lives, 24/7, to the task of making the ESO 2 for the NHS. We would also like to pay tribute to the dedication of NHS staff, the Penlon workforce, Ventilator Challenge UK members, and all key workers around the world”.
Longer-term, with an exciting future, Penlon believes that a UK manufactured, ICU ventilator would help in any future pandemic and the company are investigating how the development of this product can be funded. Penlon is looking to the future, and to establishing itself as a world-class manufacturer of Anaesthesia and Respiratory devices for the global market.
Penlon’s Development Manager talks about the ESO 2 ventilator and the VCUK consortium
Find out how the ESO 2 project started
Cliff Kersey, Development Manager at Penlon, talks about the ESO 2 Emergency Ventilator, the VentilatorChallengeUK (VCUK) consortium and working at Penlon during the coronavirus pandemic.